Six of 9 pts that died at 3 weeks were due to DILI. The APAP pts had a 3-week spontaneous survival rate of 78% compared to only 36% in the DILI group. Nine pts were seen at a mean of 26 months after enrollment which included 5 LT recipients (1 APAP, 1 DILI, 3 Other) and 4 spontaneous survivors (2 APAP, 1 DILI, 1 Other). At follow-up,7 (78%) had normal liver biochemistries and none of the LT recipients had experienced rejection or alloimmune hepatitis. CONCLUSIONS: DILI is over-represented in HIV+ ALF patients in
comparison to the overall ALFsg cohort (33% vs 10%), but is not limited to anti-retrovirals. The small number of ALF HIV + LT recipients have generally done well, indicating that LT can be offered to selected HIV+ ALF patients. Disclosures: K. Rajender Reddy
– Advisory Committees or Review Panels: Genentech-Roche, Selleckchem Rapamycin Merck, Janssen, Vertex, Gilead, BMS, Novartis, Idenix; Grant/Research Support: Genentech-Roche, Merck, BMS, Ikaria, Gilead, Hyperion, Janssen, AbbVie William M. Lee – Consulting: Eli Lilly, Novartis; Grant/Research Support: Gilead, Roche, Vertex, BI, Anadys, BMS, merck; Speaking and Teaching: Merck Robert J. Fontana – Consulting: GlaxoSmithKline, tibotec; Grant/Research Support: Gilead, vertex, Ocera The following people have nothing to disclose: Heather N. Simpson, Timothy J. Davern, Adrian Reuben, Valerie Durkalski Background and aims: There is strong evidence for an association between thrombosis in the hepatic microcirculation and liver fibrosis. Anticoagulants and antiplatelet therapy decrease liver fibrous MAPK Inhibitor Library cell assay find more tissue deposition in different animal models. The aim of this study was to evaluate liver fibrosis progression to F≥2 in liver transplant recipients with recurrent hepatitis C virus receiving or not daily low dose aspirin (75 to 100mg/d) for preventing hepatic artery thrombosis. Patients and methods: All patients HCV+ with PCR HCV+ who had undergone liver transplantation (LT) between 2000 and 2010 in 4 French centers were included in this retrospective study. Exclusion criteria were the following: HIV or HBV coinfection, previous LT, death within the year following LT. Liver fibrosis was assessed by histological
evaluation according to METAVIR classification. Data were censored at the time of antiviral therapy starting. Fibrosis progression was analysed with a multi states model with time dependant covariables. Results: 188 HCV+ patients (male 83%, mean age 52 +/-8 years) transplanted for cirrhosis were included. 109 patients received aspirin (group A) and 79 did not (group B). The mean duration to F≥2 was 4.6 years (3.5-6.3) in group A and 3.1 (1.0-9.3) in group B. There was no difference between group A and B for donor gender (83% vs 84% males), donor age (51 vs 53 years), cold ischemia time (8.2 vs 8.4 hours), episodes of acute rejection (39% vs 35%), biliary complications (20% vs 23%) and immunosuppressive therapy (calcineurin inhibitors (CNI) vs CNI + mycophenolate mofetil).